Literature DB >> 30274643

What's in a Name? Moving to Neuroscience-Based Nomenclature in Pediatric Psychopharmacology.

Ryan S Sultan1, Christoph U Correll2, Joseph Zohar3, Gil Zalsman4, Jeremy Veenstra-VanderWeele5.   

Abstract

Our traditional names for psychotropic medication classes lead to unnecessary confusion. As clinicians, we have grown comfortable with idiosyncratic names of psychotropic medications and have forgotten how unclear and misleading they can be. For example, evidence shows that serotonin reuptake inhibitors help in pediatric anxiety disorders, but a parent with an anxious child might ask, "If you diagnosed my son with separation anxiety, why are you giving him an antidepressant?" Another parent might object to the use of a "stimulant" medication, "My daughter never slows down, the last thing she needs is a stimulant!" Similarly, an "antipsychotic" can be prescribed on-label to youth with mania, bipolar depression, tics, or irritability in autism but families and patients might be confused by or object to the implied label of being "psychotic." Furthermore, patients or family members may not feel comfortable asking clarifying questions and simply do not return for follow up-concluding that the provider does not understand their child.
Copyright © 2018 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30274643      PMCID: PMC6428589          DOI: 10.1016/j.jaac.2018.05.024

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  4 in total

Review 1.  A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.

Authors:  Joseph Zohar; Stephen Stahl; Hans-Jurgen Moller; Pierre Blier; David Kupfer; Shigeto Yamawaki; Hiroyuki Uchida; Michael Spedding; Guy M Goodwin; David Nutt
Journal:  Eur Neuropsychopharmacol       Date:  2015-09-07       Impact factor: 4.600

Review 2.  Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics.

Authors:  Christoph U Correll; Christopher J Kratochvil; John S March
Journal:  J Clin Psychiatry       Date:  2011-05       Impact factor: 4.384

3.  Update on the Use of SSRIs and SNRIs with Children and Adolescents in Clinical Practice.

Authors:  E Jane Garland; Stan Kutcher; Adil Virani; Dean Elbe
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2016-02-01

4.  Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis.

Authors:  Cosima Locher; Helen Koechlin; Sean R Zion; Christoph Werner; Daniel S Pine; Irving Kirsch; Ronald C Kessler; Joe Kossowsky
Journal:  JAMA Psychiatry       Date:  2017-10-01       Impact factor: 21.596

  4 in total
  1 in total

Review 1.  Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years?

Authors:  Jeffrey R Strawn; Lu Lu; Tara S Peris; Amir Levine; John T Walkup
Journal:  J Child Psychol Psychiatry       Date:  2020-06-05       Impact factor: 8.265

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.